Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 9/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21123561 | 0.85 | PTGER1 (0.44) | PTGER1CYP1A2P2RY14 | |
| SCHEMBL1137143 | 0.85 | PTGER1 (0.59) | PTGER1CYP1A2P2RY14 | |
| SCHEMBL1233306 | 0.84 | SMN1; SMN2 (0.60) | PTGER1CYP1A2 | |
| SCHEMBL20050047 | 0.84 | PTGER1 (0.47) | PTGER1CYP1A2P2RY14 | |
| Bicarbonate SCHEMBL2360581 | 0.83 | SMN1; SMN2 (0.58) | PTGER1CYP1A2 | |
| SCHEMBL20050049 | 0.80 | PTGER1 (0.55) | PTGER1CYP1A2P2RY14 | |
| SCHEMBL22054628 | 0.80 | GAA (0.59) | PTGER1CYP1A2P2RY14 | |
| SCHEMBL21123552 | 0.77 | PTGER1 (0.38) | PTGER1CYP1A2 | |
| SCHEMBL23023643 | 0.76 | P2RY14 (0.51) | PTGER1P2RY14 | |
| SCHEMBL17324801 | 0.76 | AURKA (0.52) | PTGER1CYP1A2P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| US-20190262356-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-29 | — | — | US | disclosed |
| US-20190201413-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-20180098998-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201413-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | PTGER1 1890/4885CYP1A2 1847/4885P2RY14 3101/4885 |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | PTGER1 1890/4885CYP1A2 1847/4885P2RY14 3101/4885 |
| US-20190262356-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | PTGER1 1890/4885CYP1A2 1847/4885P2RY14 3101/4885 |
| US-20180098998-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | PTGER1 1890/4885CYP1A2 1847/4885P2RY14 3101/4885 |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | PTGER1 1890/4885CYP1A2 1847/4885P2RY14 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.